Citius Pharmaceuticals Inc. (CTXR) Financial Statements (2024 and earlier)
Company Profile
| Business Address |
11 COMMERCE DRIVE CRANFORD, NJ 07016 |
| State of Incorp. | NV |
| Fiscal Year End | September 30 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 6/30/2024 MRQ | 12/31/2023 MRQ | 9/30/2023 | 9/30/2022 | 9/30/2021 | 9/30/2020 | 9/30/2019 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 20,346 | 26,481 | 41,712 | 70,073 | 13,860 | 7,894 | |||
| Cash and cash equivalents | 20,346 | 26,481 | 41,712 | 70,073 | 13,860 | 7,894 | |||
| Prepaid expense | 7,864 | 7,890 | 2,853 | 2,741 | 122 | 48 | |||
| Total current assets: | 28,210 | 34,370 | 44,564 | 72,814 | 13,982 | 7,942 | |||
| Noncurrent Assets | |||||||||
| Operating lease, right-of-use asset | 404 | 454 | 646 | 823 | 986 | 1,138 | |||
| Property, plant and equipment | 1 | 1 | 4 | 7 | 2 | 1 | |||
| Intangible assets, net (including goodwill) | 9,347 | 9,347 | 9,347 | 9,347 | 9,347 | 1,587 | |||
| Goodwill | 9,347 | 9,347 | 9,347 | 9,347 | 9,347 | 1,587 | |||
| Other undisclosed noncurrent assets | 59,438 | 59,438 | 59,438 | 59,438 | 19,457 | 18,319 | |||
| Total noncurrent assets: | 69,190 | 69,241 | 69,435 | 69,615 | 29,792 | 21,044 | |||
| TOTAL ASSETS: | 97,400 | 103,611 | 113,999 | 142,429 | 43,774 | 28,986 | |||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities | 2,924 | 3,404 | 4,333 | 3,805 | 3,765 | 4,435 | |||
| Interest and dividends payable | ✕ | ✕ | ✕ | ✕ | 90 | 74 | |||
| Employee-related liabilities | ✕ | ✕ | ✕ | 1,762 | 1,906 | 1,655 | 1,401 | ||
| Accounts payable | 2,647 | 2,927 | 1,165 | 1,277 | 1,856 | 2,714 | |||
| Accrued liabilities | 277 | 476 | 1,405 | 622 | 164 | 246 | |||
| Debt | 173 | 173 | |||||||
| Other undisclosed current liabilities | 2,655 | 2,375 | 197 | 177 | 159 | ||||
| Total current liabilities: | 5,579 | 5,779 | 4,530 | 3,982 | 4,097 | 4,608 | |||
| Noncurrent Liabilities | |||||||||
| Long-term debt and lease obligation | 481 | 678 | 1,020 | ||||||
| Long-term debt, excluding current maturities | 165 | ||||||||
| Liabilities, other than long-term debt | 6,486 | 6,401 | 5,562 | 4,986 | 4,986 | ||||
| Deferred income tax liabilities | 6,282 | 6,138 | 5,562 | 4,986 | 4,986 | ||||
| Operating lease, liability | 205 | 263 | 481 | 678 | 855 | ||||
| Total noncurrent liabilities: | 6,486 | 6,401 | 6,043 | 5,664 | 6,006 | ||||
| Total liabilities: | 12,065 | 12,180 | 10,573 | 9,646 | 10,103 | 4,608 | |||
| Equity | |||||||||
| Equity, attributable to parent | 84,734 | 90,831 | 102,826 | 132,182 | 33,671 | 24,379 | |||
| Common stock | 159 | 159 | 146 | 146 | 56 | 29 | |||
| Additional paid in capital | 256,038 | 252,904 | 232,368 | 228,084 | 104,209 | 80,170 | |||
| Accumulated deficit | (171,463) | (162,231) | (129,688) | (96,048) | (70,594) | (55,820) | |||
| Equity, attributable to noncontrolling interest | 600 | 600 | 600 | 600 | |||||
| Total equity: | 85,335 | 91,431 | 103,426 | 132,783 | 33,671 | 24,379 | |||
| TOTAL LIABILITIES AND EQUITY: | 97,400 | 103,611 | 113,999 | 142,429 | 43,774 | 28,986 | |||
Income Statement (P&L) ($ in thousands)
| 6/30/2024 TTM | 12/31/2023 TTM | 9/30/2023 | 9/30/2022 | 9/30/2021 | 9/30/2020 | 9/30/2019 | ||
|---|---|---|---|---|---|---|---|---|
| Revenues | 90 | 90 | 110 | 90 | ||||
| Other income | 60 | 110 | ||||||
| Gross profit: | 90 | 90 | 110 | 90 | ||||
| Operating expenses | (38,823) | (36,732) | (33,316) | (23,532) | (17,711) | (15,598) | ||
| Other undisclosed operating loss | (90) | (90) | (110) | (90) | ||||
| Operating loss: | (38,823) | (36,732) | (33,316) | (23,532) | (17,711) | (15,598) | ||
| Nonoperating income | 4,804 | 4,765 | 251 | 477 | 163 | 36 | ||
| Investment income, nonoperating | 894 | 1,179 | 251 | 262 | 68 | 53 | ||
| Other nonoperating income | 3,586 | |||||||
| Interest and debt expense | 322 | (16) | (16) | |||||
| Other undisclosed loss from continuing operations before equity method investments, income taxes | (3,586) | |||||||
| Loss from continuing operations before equity method investments, income taxes: | (37,604) | (31,967) | (33,065) | (22,732) | (17,564) | (15,579) | ||
| Other undisclosed income (loss) from continuing operations before income taxes | 16 | 31,141 | ||||||
| Income (loss) from continuing operations before income taxes: | (37,604) | (31,967) | (33,065) | (22,732) | (17,548) | 15,562 | ||
| Income tax expense | (576) | (576) | (576) | (1) | ||||
| Income (loss) from continuing operations: | (38,180) | (32,543) | (33,641) | (22,733) | (17,548) | 15,562 | ||
| Income (loss) before gain (loss) on sale of properties: | ✕ | ✕ | ✕ | (33,641) | (22,733) | (17,548) | 15,562 | |
| Other undisclosed net loss | (321) | (31,124) | ||||||
| Net loss attributable to parent: | (38,180) | (32,543) | (33,641) | (23,054) | (17,548) | (15,562) | ||
| Preferred stock dividends and other adjustments | (1,451) | |||||||
| Other undisclosed net loss available to common stockholders, basic | (1,151) | (1,151) | ||||||
| Net loss available to common stockholders, diluted: | (39,332) | (33,694) | (33,641) | (24,505) | (17,548) | (15,562) | ||
Comprehensive Income ($ in thousands)
| 6/30/2024 TTM | 12/31/2023 TTM | 9/30/2023 | 9/30/2022 | 9/30/2021 | 9/30/2020 | 9/30/2019 | ||
|---|---|---|---|---|---|---|---|---|
| Net loss: | (38,180) | (32,543) | (33,641) | (23,054) | (17,548) | (15,562) | ||
| Comprehensive loss, net of tax, attributable to parent: | (38,180) | (32,543) | (33,641) | (23,054) | (17,548) | (15,562) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.